Scarica l'app Stockscreener
0.1674
15.93%
0.023
Dopo l'orario di chiusura:
.17
0.0026
+1.55%
Precedente Chiudi:
$0.1444
Aprire:
$0.1524
Volume 24 ore:
156.79M
Relative Volume:
2.39
Capitalizzazione di mercato:
$44.37M
Reddito:
$175.04M
Utile/perdita netta:
$-44.52M
Rapporto P/E:
-0.93
EPS:
-0.18
Flusso di cassa netto:
$-56.05M
1 W Prestazione:
+151.35%
1M Prestazione:
+194.20%
6M Prestazione:
-42.43%
1 anno Prestazione:
-83.19%
Intervallo 1D:
$0.151
$0.1936
Intervallo di 1 settimana:
$0.0735
$0.225
Portata 52W:
$0.0403
$1.01
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Nome
Adaptimmune Therapeutics Plc Adr
Settore
Industria
Telefono
44 1235 430000
Indirizzo
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Confronta ADAP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.1674 | 38.27M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.13 | 98.23B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.68 | 62.74B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.92 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
740.03 | 45.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
337.81 | 36.81B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-06-26 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-07-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Outperform |
| 2023-03-24 | Iniziato | Bryan Garnier | Buy |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-09 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-05-28 | Iniziato | Barclays | Underweight |
| 2020-04-22 | Iniziato | Mizuho | Neutral |
| 2019-08-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-05-31 | Iniziato | ROTH Capital | Buy |
| 2019-05-30 | Ripresa | Citigroup | Buy |
| 2019-05-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | Iniziato | Wells Fargo | Market Perform |
| 2016-10-24 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | Iniziato | Raymond James | Outperform |
| 2016-02-25 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | BofA/Merrill | Neutral |
| 2015-06-01 | Iniziato | Guggenheim | Buy |
| 2015-06-01 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Adaptimmune Therapeutics Plc Adr Borsa (ADAP) Ultime notizie
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Best Momentum Stocks to Buy for July 31st - Yahoo Finance
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m By Investing.com - Investing.com India
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
KANZHUN LIMITED Sponsored ADR (BZ) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - Yahoo Finance
All Markets & Instruments Available to Trade - Capital.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Adaptimmune Therapeutics Plc Adr Azioni (ADAP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):